JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Jazz Pharmaceuticals plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$208.43−1.80 (-0.86%)
Close on Oct 19, 2026
- Market cap
- $14.47B
- P/E (TTM)
- 14.3
- Dividend yield
- –
Jazz Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $13.53B | $197.05M |
| Enterprise Value | $15.68B | $106.56M |
| PE Ratio | 14.26 | 20.52 |
| PS Ratio | 2.94 | 3.93 |
| PB Ratio | 2.82 | 2.14 |
| P/FCF Ratio | 8.50 | 18.25 |
| P/OCF Ratio | 8.15 | 13.78 |
Enterprise value
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 3.41 | 2.69 |
| EV / EBITDA | 17.49 | 14.86 |
| EV / EBIT | 17.49 | 19.00 |
| EV / FCF | 9.85 | 21.02 |
Income (trailing twelve months)
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $4.60B | $57.94M |
| Operating Income | $896.84M | -$21.44M |
| Pretax Income | $727.71M | -$14.45M |
| Net Income | $940.76M | -$22.46M |
| EBITDA | $896.84M | -$16.91M |
| EPS (Diluted) | $14.62 | -$0.83 |
Margins
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | 19.5% | -44.5% |
| Pretax Margin | 15.8% | -13.0% |
| Profit Margin | 20.4% | -39.2% |
| EBITDA Margin | 19.5% | -31.3% |
| FCF Margin | 34.6% | -8.85% |
Returns
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 22.1% | -53.1% |
| Return on Assets (ROA) | 8.54% | -41.0% |
| Return on Invested Capital (ROIC) | 12.1% | -32.0% |
| Return on Capital Employed (ROCE) | 10.1% | -37.8% |
Growth
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 12.6% | 6.01% |
| FCF Growth (YoY) | 25.8% | 2.34% |
| Revenue Growth (3Y CAGR) | 5.26% | 2.25% |
| Revenue Growth (5Y CAGR) | 12.5% | 6.42% |
Balance sheet
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.20B | $62.42M |
| Total Debt | $4.35B | $120.13M |
| Net Cash (Debt) | -$2.15B | $15.68M |
| Net Cash Per Share | -$33.15 | $0.65 |
| Equity (Book Value) | $4.80B | $48.79M |
| Book Value Per Share | $73.97 | $1.36 |
| Tangible Book Value | -$1.03B | $23.06M |
| Working Capital | $1.74B | $75.77M |
Financial position
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 1.78 | 3.30 |
| Quick Ratio | 1.38 | 2.39 |
| Debt / Equity | 0.91 | 0.51 |
| Debt / EBITDA | 4.85 | 3.35 |
| Debt / FCF | 2.73 | 5.05 |
| Net Debt / EBITDA | 2.40 | 2.22 |
Cash flow (trailing twelve months)
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $1.66B | -$12.35M |
| Capital Expenditures | -$69.75M | -$1.06M |
| Free Cash Flow | $1.59B | -$20.28M |
| FCF Per Share | $24.51 | -$0.41 |
Efficiency
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.42 | 0.38 |
| Revenue Per Employee | $1.59M | $398.96K |
| Profits Per Employee | $325.52K | -$732.08K |
| Employee Count | 2,890 | 73 |
Dividends and yields
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 6.95% | -21.2% |
| FCF Yield | 11.8% | -7.64% |
Shares
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 64,914,600 | 59,128,900 |
| Shares Change (YoY) | 4.58% | 11.1% |
| Float | 62,686,600 | 48,744,500 |
| Shares Held by Insiders | 3.43% | 11.8% |
| Shares Held by Institutions | 99.2% | 59.4% |
Taxes
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$213.26M | $91.50K |
| Effective Tax Rate | -29.3% | 20.6% |
Scores
| Measure | Jazz Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $155.99 | $17.36 |
| Graham Upside | -25.2% | -45.5% |
| Altman Z-Score | 2.31 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Jazz Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.